Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy.

ABSTRACT:

Objective

The aim of this study was to assess the prevalence of cytomegalovirus (CMV) viremia in HIV-positive patients starting antiretroviral therapy (ART) and to evaluate its impact on clinical outcomes.

Design

A retrospective analysis of four clinical trials (INSIGHT FIRST, SMART, START, and ANRS REFLATE TB).

Methods

Stored plasma samples from participants were used to measure CMV viremia at baseline prior to initiating ART and at visits through 1 year of follow-up after ART initiation. CMV viremia was measured centrally using a quantitative PCR assay. Within FIRST, associations of CMV viremia at baseline and through 8 months of ART were examined with a composite clinical outcome of AIDS, serious non-AIDS events, or death using Cox proportional hazards regression.<

SUBMITTER: Levi LI 

PROVIDER: S-EPMC9980657 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature